Literature DB >> 19818375

The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers.

Nicolas Jonckheere1, Isabelle Van Seuningen.   

Abstract

The membrane-bound mucins belong to an ever-increasing family of O-glycoproteins. Based on their structure and localization at the cell surface they are thought to play important biological roles in cell-cell and cell-matrix interactions, in cell signalling and in modulating biological properties of cancer cells. Among them, MUC1 and MUC4 mucins are best characterized. Their altered expression in cancer (overexpression in the respiratory, gastro-intestinal, urogenital and hepato-biliary tracts) indicates an important role for these membrane-bound mucins in tumour progression, metastasis, cancer cell resistance to chemotherapeutics drugs and as specific markers of epithelial cancer cells. Some mechanisms responsible for MUC1 and MUC4 role in tumour cell properties have been deciphered recently. However, much remains to be done in order to understand the molecular mechanisms and signalling pathways that control the expression of membrane-bound mucins during the different steps of tumour progression toward adenocarcinoma and evaluate their potential as prognostic/diagnostic markers and as therapeutic tools. In this review we focus on the molecular mechanisms and signalling pathways known to control the expression of membrane-bound mucins in cancer. We will discuss the mechanisms of regulation at the promoter level (including genetic and epigenetic modifications) that may be responsible for the mucin altered pattern of expression in epithelial cancers. 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818375     DOI: 10.1016/j.biochi.2009.09.018

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  54 in total

1.  Molecular Validation of PACE4 as a Target in Prostate Cancer.

Authors:  François D'Anjou; Sophie Routhier; Jean-Pierre Perreault; Alain Latil; David Bonnel; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.

Authors:  Mengying Yao; Weihong Zhang; Qingxian Zhang; Lihua Xing; Aiguo Xu; Qiuhong Liu; Bing Cui
Journal:  Lung       Date:  2011-10-01       Impact factor: 2.584

3.  Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

Authors:  Robin R Hodges; Darlene A Dartt
Journal:  Exp Eye Res       Date:  2013-08-14       Impact factor: 3.467

Review 4.  Mucin-based targeted pancreatic cancer therapy.

Authors:  Maria P Torres; Subhankar Chakraborty; Joshua Souchek; Surinder K Batra
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 5.  Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Authors:  Muzafar A Macha; Shiv Ram Krishn; Rahat Jahan; Kasturi Banerjee; Surinder K Batra; Maneesh Jain
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

6.  miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.

Authors:  F Lahdaoui; Y Delpu; A Vincent; F Renaud; M Messager; B Duchêne; E Leteurtre; C Mariette; J Torrisani; N Jonckheere; I Van Seuningen
Journal:  Oncogene       Date:  2014-03-10       Impact factor: 9.867

7.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

Review 8.  Defensins, lectins, mucins, and secretory immunoglobulin A: microbe-binding biomolecules that contribute to mucosal immunity in the human gut.

Authors:  Phoom Chairatana; Elizabeth M Nolan
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-11-13       Impact factor: 8.250

9.  A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance.

Authors:  Xiuling Xu; Alexandria Wells; Mabel T Padilla; Kosuke Kato; Kwang Chul Kim; Yong Lin
Journal:  Carcinogenesis       Date:  2014-08-01       Impact factor: 4.944

10.  Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.

Authors:  Eric Hastie; Dahlia M Besmer; Nirav R Shah; Andrea M Murphy; Megan Moerdyk-Schauwecker; Carlos Molestina; Lopamudra Das Roy; Jennifer M Curry; Pinku Mukherjee; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.